Skip to main content
Fig. 8 | Cancer Cell International

Fig. 8

From: The troglitazone derivative EP13 disrupts energy metabolism through respiratory chain complex I inhibition in breast cancer cells and potentiates the antiproliferative effect of glycolysis inhibitors

Fig. 8

EP13 and oxamate act synergistically to kill breast cancer cells. MDA-MB-231 cells were treated for 72 h with EP13 (1 and 3 µM) and increasing concentrations of oxamate, a glycolytic inhibitor, used alone or in combination. Cell numbers were determined by crystal violet staining (a). The results are depicted as the mean ± SEM of at least three independent measurements. Two-way analysis of variance (ANOVA) followed by the Dunnett multiple comparisons posttest were performed. Significant differences from control cells are indicated (**, p < 0.01; ***, p < 0.001). Data were analysed by Compusyn software to determine the combination index (CI) with a nonconstant ratio according to the Chou Talalay method (b). The area between the dashed line (0.9 < CI < 1.1) is related to an additive effect. A CI > 1.1 indicates an antagonistic effect, and a CI < 0.9 indicates a synegistic effect

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us